Deal Watch: Roche Aborts But Regeneron, Amgen and Pfizer Sign Up

Deal activity over the past seven days sees Roche knock back Inovio a second time, Regeneron plan for its future via an alliance with Adicet Bio, Amgen supplement its preclinical pipeline with a candidate from Advaxis, and Pfizer shore up its gene therapy ambitions with an acquisition.

StacksOfPapers_1200x675

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy transactions that occurred between July 31 and August 5. Deal Watch is supported by deal intelligence from Strategic Transactions.

Roche has decided to break off its deal with Inovio Pharmaceuticals Inc. for the development of hepatitis B...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip